Jeremy Larsen is an Oncology physician. OpenAlex indexes 84 publications with 1,342 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
14200 W Celebrate Life Way
Goodyear, AZ 853383007
Telephone
623-207-3000Provider last certified this registry record 4 Jan 2024.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20258 payments$20,093openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20253 payments
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
39.5%Thalidomide Analog34.1%Lenalidomide67%Revlimid33%Part D<11 patientsKinase inhibitor5.5%Brukinsa100%Part D<11 patientsDermatology
20%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor20%Acyclovir100%Part D≥19 patientsMetabolism & gastrointestinal
15%Serotonin-3 Receptor Antagonist8.2%Ondansetron Hcl100%Part D≥11 patientsProton pump inhibitor6.8%Pantoprazole Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma
Leukemia & lymphoma/Leukemia and lymphoma
2024 - Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia
2023 - Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
Blood Cancer Journal
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”